Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BMS-986449 alone and with nivolumab in advanced solid tumors
2023-503484-42-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of BMS-986449 and nivolumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and dose-limiting toxicities. Planned start Oct 2023; status: authorised.
02
Drugs
BMS-986449nivolumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-503484-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503484-42-00.